Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses
Felix Bayerl(Technical University of Munich), Jan P. Böttcher(University Children's Hospital Tübingen), Simon Grassmann(Technical University of Munich), Anna Hirschberger(Technical University of Munich), Lukas Ramsauer(Technical University of Munich), Anais Elewaut(Vienna Biocenter), Dirk Schadendorf(National Center for Tumor Diseases), Moritz Knolle(Technical University of Munich), Veit R. Buchholz(German Cancer Research Center), Bastian Höchst(Technical University of Munich), Rupert Öllinger(Technical University of Munich), Barbara U. Schraml(Centre of Experimental Medicine of the Slovak Academy of Sciences), Chris D. Hermann(Optech (Canada)), Dirk Wohlleber(TUM Klinikum), Marcel P. Trefny(LMU Klinikum), Anne Zaremba(National Center for Tumor Diseases), Alfred Zippelius(University of Basel), Achim Krüger(Technical University of Munich), Anna‐Marie Pedde(Technical University of Munich), Sainitin Donakonda(German Center for Infection Research), Anna C. Obenauf(Research Institute of Molecular Pathology), Roland Rad(ING Direct), Martina Anton(Technical University of Munich), Philippa Meiser(Technical University of Munich), Nicole Kirchhammer(University of Basel), Sebastian Lacher(Servier (Germany)), Thomas Rudolph(University of Minnesota)
Cited by 176
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
|Immunity|2013|4.7k
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
|Journal of Clinical Oncology|2015|2.1k
Metastatic colonization by circulating tumour cells
|Nature|2016|2k